LAVA Therapeutics N.V. (LVTX)의 가격은 얼마입니까?

LAVA Therapeutics N.V. (LVTX)의 가격은 $1.74입니다.

LAVA Therapeutics N.V. (LVTX)의 시가 총액은 무엇입니까?

LAVA Therapeutics N.V. (LVTX)의 시가 총액은 $45.77M입니다.

LAVA Therapeutics N.V. (LVTX) 발행주식수

LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.

연도	발행 주식 수	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

발행 주식 수

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	발행 주식 수	차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	483.58M	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	396.00M	-	US

회사

발행 주식 수

차이

국가